Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2015 - 2026)
Sunshine Biopharma (SBFM) posted Depreciation & Amortization (CF) of $76859.0 for Q1 2026, down 22.03% on a QoQ basis from $98581.0 in Q4 2025, and up 18.62% year-over-year from $64793.0 in Q1 2025.
Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Sunshine Biopharma's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $76859.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 18.62% year-over-year to $76859.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344136.0 (up 40.06% YoY) and the FY2025 annual result came in at $332070.0, up 48.56% from the prior year.
- Depreciation & Amortization (CF) was $76859.0 for Q1 2026 at Sunshine Biopharma, down from $98581.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $98581.0 in Q4 2025 and bottomed at $789.0 in Q3 2022.
- A 5-year average of $47456.8 and a median of $42618.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 75.21% — and 2023, when it soared 4614.83%.
- Sunshine Biopharma's Depreciation & Amortization (CF) stood at $18977.0 in 2022, then soared by 123.18% to $42353.0 in 2023, then soared by 54.41% to $65399.0 in 2024, then surged by 50.74% to $98581.0 in 2025, then decreased by 22.03% to $76859.0 in 2026.
- Business Quant data shows SBFM's Depreciation & Amortization (CF) at $76859.0 in Q1 2026, $98581.0 in Q4 2025, and $96163.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 22.60 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 76,859.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,859.00 |
| Mar 31, 2026 | 76,859.00 |
| Dec 31, 2025 | 98,581.00 |
| Dec 31, 2025 | 98,581.00 |
| Sep 30, 2025 | 96,163.00 |
| Sep 30, 2025 | 96,163.00 |
| Jun 30, 2025 | 72,533.00 |
| Jun 30, 2025 | 72,533.00 |
| Mar 31, 2025 | 64,793.00 |
| Mar 31, 2025 | 64,793.00 |
| Dec 31, 2024 | 65,399.00 |
| Dec 31, 2024 | 65,399.00 |
| Sep 30, 2024 | 64,634.00 |
| Sep 30, 2024 | 64,634.00 |
| Jun 30, 2024 | 50,876.00 |
| Jun 30, 2024 | 50,876.00 |
| Mar 31, 2024 | 42,618.00 |
| Mar 31, 2024 | 42,618.00 |
| Dec 31, 2023 | 42,353.00 |
| Dec 31, 2023 | 42,353.00 |